Brenda D G Lerner

Brenda D G Lerner

Auto-generated profile, based on publicly available information

Brenda D G Lerner

Florida International University, Miami, FL, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of the Association of Nurses in AIDS Care
Verified
Journal Article
Open access
Jennifer AttonitoJennifer Attonito
Jennifer Attonito
JDJessy G Devieux
Jessy G Devieux
BLBrenda D.G. Lerner
Brenda D.G. Lerner
MHMichelle Hospital
Michelle Hospital
RRRhonda Rosenberg
Rhonda Rosenberg
Psychosocial factors may directly impact HIV health measures such as viral load (VL) whether or not patients are taking antiretroviral treatment (ART) consistently. Structural equation modeling plusBaron and Kenny's (1986)four-step approach were used to test a mediated model predicting VL among 246 HIV-infected adults who were on ART. Exogenous variables were social support, barriers to adherence, and stress. Moderators were alcohol use, marijuana use, and neurocognitive impairment. A small positive association between marijuana use and ART adherence approached significance. Only barriers to adherence predicted a decrease in adherence rates and an increase in VL. No other factors were significantly associated with either VL or adherence, and no interaction effects between exogenous variables and moderators were identified. The association between barriers to adherence and VL was partially mediated by ART adherence. Findings provide modest support for a direct link between psychosocial variables and a virologic response to ART.

7 May 2022 in Journal of Clinical Psychology in Medical Settings
Verified
Journal Article
Closed access
PDF file
JDJessy G Devieux
Jessy G Devieux
RRR. Rosenberg
R. Rosenberg
DLDr. Brenda Lerner
Dr. Brenda Lerner
KVK. Villalba
K. Villalba
Jennifer AttonitoJennifer Attonito
Jennifer Attonito
JSJoel Stein
Joel Stein

18 October 2023 in JMIR Preprints
Verified
Preprint
Open access
RCRobert L Cook
Robert L Cook
VRVeronica Richards
Veronica Richards
JGJoseph M Gullett
Joseph M Gullett
BLBrenda D G Lerner
Brenda D G Lerner
ZZZhi Zhou
Zhi Zhou
RCRonald A Cohen
Ronald A Cohen
BACKGROUND Both alcohol consumption and HIV infection are associated with worse brain, cognitive, and clinical outcomes in older adults. However, the extent to which brain and cognitive dysfunction is reversible with reduction or cessation of drinking is unknown. OBJECTIVE The 30-Day Challenge study was designed to determine whether reduction or cessation of drinking would be associated with improvements in cognition, reduction of systemic and brain inflammation, and improvement in HIV-related outcomes in adults with heavy drinking. METHODS The study design was a mechanistic experimental trial, in which all participants received an alcohol reduction intervention followed by repeated assessments of behavioral and clinical outcomes. Persons were eligible if they were 45 years of age or older, had weekly alcohol consumption of 21 or more drinks (men) or 14 or more drinks (women), and were not at high risk of alcohol withdrawal. After a baseline assessment, participants received an intervention consisting of contingency management (money for nondrinking days) for at least 30 days followed by a brief motivational interview. After this, participants could either resume drinking or not. Study questionnaires, neurocognitive assessments, neuroimaging, and blood, urine, and stool samples were collected at baseline, 30 days, 90 days, and 1 year after enrollment. RESULTS We enrolled 57 persons with heavy drinking who initiated the contingency management protocol (mean age 56 years, SD 4.6 years; 63%, n=36 male, 77%, n=44 Black, and 58%, n=33 people with HIV) of whom 50 completed 30-day follow-up and 43 the 90-day follow-up. The planned study procedures were interrupted and modified due to the COVID-19 pandemic of 2020-2021. CONCLUSIONS This was the first study seeking to assess changes in brain (neuroimaging) and cognition after alcohol intervention in nontreatment-seeking people with HIV together with people without HIV as controls. Study design strengths, limitations, and lessons for future study design considerations are discussed. Planned analyses are in progress, after which deidentified study data will be available for sharing. CLINICALTRIAL ClinicalTrials.gov NCT03353701; https://clinicaltrials.gov/study/NCT03353701 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/53684

2 April 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
RCRobert L Cook
Robert L Cook
VRVeronica Richards
Veronica Richards
JGJoseph M Gullett
Joseph M Gullett
BLBrenda D G Lerner
Brenda D G Lerner
ZZZhi Zhou
Zhi Zhou
TTThe 30-Day Challenge Research Team
The 30-Day Challenge Research Team
Background: Both alcohol consumption and HIV infection are associated with worse brain, cognitive, and clinical outcomes in older adults. However, the extent to which brain and cognitive dysfunction is reversible with reduction or cessation of drinking is unknown. Objective: The 30-Day Challenge study was designed to determine whether reduction or cessation of drinking would be associated with improvements in cognition, reduction of systemic and brain inflammation, and improvement in HIV-related outcomes in adults with heavy drinking. Methods: The study design was a mechanistic experimental trial, in which all participants received an alcohol reduction intervention followed by repeated assessments of behavioral and clinical outcomes. Persons were eligible if they were 45 years of age or older, had weekly alcohol consumption of 21 or more drinks (men) or 14 or more drinks (women), and were not at high risk of alcohol withdrawal. After a baseline assessment, participants received an intervention consisting of contingency management (money for nondrinking days) for at least 30 days followed by a brief motivational interview. After this, participants could either resume drinking or not. Study questionnaires, neurocognitive assessments, neuroimaging, and blood, urine, and stool samples were collected at baseline, 30 days, 90 days, and 1 year after enrollment. Results: We enrolled 57 persons with heavy drinking who initiated the contingency management protocol (mean age 56 years, SD 4.6 years; 63%, n=36 male, 77%, n=44 Black, and 58%, n=33 people with HIV) of whom 50 completed 30-day follow-up and 43 the 90-day follow-up. The planned study procedures were interrupted and modified due to the COVID-19 pandemic of 2020-2021. Conclusions: This was the first study seeking to assess changes in brain (neuroimaging) and cognition after alcohol intervention in nontreatment-seeking people with HIV together with people without HIV as controls. Study design strengths, limitations, and lessons for future study design considerations are discussed. Planned analyses are in progress, after which deidentified study data will be available for sharing. Trial Registration: ClinicalTrials.gov NCT03353701; https://clinicaltrials.gov/study/NCT03353701 International Registered Report Identifier (IRRID): DERR1-10.2196/53684